Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arena Says Patient Programs Will Offset Belviq’s Premium Price For Some

This article was originally published in The Pink Sheet Daily

Executive Summary

The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.

You may also be interested in...



Vivus Beefs Up Qsymia Efforts As Eisai Prepares To Launch Belviq

The obesity drug market will see substantial commercial investment in the second half of 2013. Vivus is planning its first DTC advertising for Qsymia and continuing its search for a big pharma partner, while Eisai/Arena have been cleared by the Drug Enforcement Agency to launch Belviq.

Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch

With a July 17 user fee date, Vivus’ obesity drug Qnexa could beat Arena Pharmaceuticals’ Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.

Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date

In addition to upfront and milestone payments, deal also includes effective royalties above 30 percent of annual net sales.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel